IPSC — Century Therapeutics Share News
0.000.00%
Last trade - 00:00- $264.37m
- $144.66m
- $109.16m
Brief: Century Therapeutics Reports Full Year 2022 Financial Results
Brief: Century Therapeutics Maintains About $3 Mln Of Cash, Cash Equivalents With SVB
Brief: Century Therapeutics Announces First Patient Dosed In First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 In Relapsed Or Refractory CD19 Positive B-Cell Lymphomas
U.S. RESEARCH ROUNDUP- Humana, JP Morgan, Voya Financial
Brief: Century Therapeutics Announces Internal Portfolio Prioritization To Extend Cash Runway Into 2026
U.S. RESEARCH ROUNDUP-Century Therapeutics, Mastec, Quanta Services
Brief: Century Therapeutics Provides Pipeline Updates
U.S. RESEARCH ROUNDUP- Coca-Cola, Five9, Texas Instruments
Brief: Century Therapeutics Announces Appointment Of Daphne Quimi And Timothy Walbert To Its Board
Brief: Century Therapeutics Receives Study May Proceed Notification From FDA For CNTY-101 To Overcome Three Major Pathways Of Host Versus Graft Rejection
Brief: Century Therapeutics Reports Second Quarter 2022 Financial Results
Brief: Century Therapeutics Entered Into Sales Agreement With Cowen And Company
Brief: Century Therapeutics Inc Files For Mixed Shelf Of Up To $500 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:04 AM
Brief: Century Therapeutics Announces Its Addition To The Russell Microcap Index
U.S. RESEARCH ROUNDUP-Helmerich and Payne, J B Hunt Transport Services, Stratasys
Brief: Century Therapeutics Reports Qtrly Loss Per Share $0.66
U.S. RESEARCH ROUNDUP-Hub Group, Varonis Systems, WEX
Brief: Century Therapeutics Reports Q4, Year-End 2021 Financial Results